Therapeutic agent for motor disorders

Abstract

Provided are an agent for the treatment and/or prophylaxis of a movement disorder, the agent for the treatment and/or prophylaxis wherein the movement disorder is extrapyramidal syndrome, the agent for the treatment and/or prophylaxis wherein the movement disorder is bradykinesia, gait disturbance, dystonia, dyskinesia or tardive dyskinesia, the agent for the treatment and/or prophylaxis wherein the movement disorder is a side effect of L-DOPA and/or dopamine agonist therapy, and the like, each containing a thiazole derivative represented by the formula (I) wherein R 1 represents aryl and the like, and R 2 represents pyridyl or the like, or a pharmaceutically acceptable salt thereof as an active ingredient.

1 - 78 . (canceled) 
     
     
         79 . A method of treating and/or preventing progression of a motor complication caused by L-DOPA and/or dopamine agonist therapy, comprising the steps of:
 administering to a patient undergoing L-DOPA and/or dopamine agonist therapy an effective amount of a thiazole derivative or a pharmaceutically acceptable salt thereof, wherein said thiazole derivative is represented by any of formulae (IA)-(IAA)   
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         80 . The method according to  claim 79 , wherein the motor complication is wearing-off phenomenon. 
     
     
         81 . The method according to  claim 79 , wherein the motor complication is on-off fluctuation. 
     
     
         82 . The method according to  claim 79 , wherein the motor complication is dyskinesia. 
     
     
         83 . The method according to  claim 79 , wherein said motor complication is caused by L-DOPA therapy and said patient is undergoing L-DOPA therapy. 
     
     
         84 . The method according to  claim 79 , wherein said motor complication is caused by dopamine agonist therapy and said patient is undergoing dopamine agonist therapy. 
     
     
         85 . The method according to  claim 80 , wherein said motor complication is caused by L-DOPA therapy and said patient is undergoing L-DOPA therapy. 
     
     
         86 . The method according to  claim 80 , wherein said motor complication is caused by dopamine agonist therapy and said patient is undergoing dopamine agonist therapy. 
     
     
         87 . The method according to  claim 81 , wherein said motor complication is caused by L-DOPA therapy and said patient is undergoing L-DOPA therapy. 
     
     
         88 . The method according to  claim 81 , wherein said motor complication is caused by dopamine agonist therapy and said patient is undergoing dopamine agonist therapy. 
     
     
         89 . The method according to  claim 82 , wherein said motor complication is caused by L-DOPA therapy and said patient is undergoing L-DOPA therapy. 
     
     
         90 . The method according to  claim 82 , wherein said motor complication is caused by dopamine agonist therapy and said patient is undergoing dopamine agonist therapy.